{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:00:04Z","timestamp":1790787604732,"version":"4.1.0"},"reference-count":233,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":123,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bbmt.2020.09.020","type":"journal-article","created":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T01:33:17Z","timestamp":1600565597000},"page":"6-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Bhagirathbhai","family":"Dholaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty K.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien D.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan Octavian","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa G.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon L. Phillips","family":"II","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"El Chaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AlFadel","family":"AlShaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Majhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.09.020_bib0001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2007.11.002","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review","volume":"14","author":"Oliansky","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0002","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","article-title":"A new system for grading recommendations in evidence based guidelines","volume":"323","author":"Harbour","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0003","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2009.02.008","article-title":"Methodology for updating published evidence-based reviews evaluating the role of blood and marrow transplantation in the treatment of selected diseases: a policy statement by the American Society for Blood and Marrow Transplantation","volume":"15","author":"Jones","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0004","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjh.12425","article-title":"Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study","volume":"162","author":"Shah","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0006","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0007","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood.V98.6.1746","article-title":"Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification","volume":"98","author":"San Miguel","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0008","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?","volume":"109","author":"Cornelissen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0009","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/cncr.20945","article-title":"Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis","volume":"103","author":"Yanada","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0010","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/leu.2014.335","article-title":"Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial","volume":"29","author":"Schetelig","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0011","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2008-10-182592","article-title":"Quality of life after allogeneic hematopoietic cell transplantation","volume":"114","author":"Pidala","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0013","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0014","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461","volume":"22","author":"Byrd","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0015","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2008-03-145862","article-title":"Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes","volume":"113","author":"Kuwatsuka","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0016","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0017","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood-2014-01-549212","article-title":"Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup","volume":"124","author":"Hospital","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0018","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0019","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B","volume":"108","author":"Frohling","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0020","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/cncr.24367","article-title":"Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia","volume":"115","author":"Borthakur","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0021","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1309\/AJCP5ETHDXO6NCGZ","article-title":"Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome","volume":"131","author":"Gustafson","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0022","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","article-title":"Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup","volume":"22","author":"Schlenk","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0023","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbmt.2007.10.006","article-title":"HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR","volume":"14","author":"Schlenk","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0026","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.2013.54.4973","article-title":"Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial","volume":"33","author":"R\u00f6llig","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0027","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/bloodadvances.2018020305","article-title":"Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia","volume":"2","author":"Sakaguchi","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0028","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3324\/haematol.2015.135681","article-title":"Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status","volume":"101","author":"Bazarbachi","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0029","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0030","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood-2013-05-503847","article-title":"The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA","volume":"122","author":"Schlenk","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0031","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0032","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0033","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0034","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2016-05-670240","article-title":"How I diagnose and manage individuals at risk for inherited myeloid malignancies","volume":"128","author":"Drazer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0035","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0036","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbmt.2019.09.006","article-title":"Novel disease risk model for patients with acute myeloid leukemia receiving allogeneic hematopoietic cell transplantation","volume":"26","author":"Kongtim","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0037","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0038","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0039","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41409-018-0413-0","article-title":"Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation","volume":"54","author":"Grimm","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0041","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0042","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.3390\/ijms20215362","article-title":"The role of measurable residual disease (MRD) in hematopoietic stem cell transplantation for hematological malignancies focusing on acute leukemia","volume":"20","author":"Czyz","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0043","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0044","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/MOH.0b013e3283366b7a","article-title":"Induction therapy in acute myeloid leukemia: intensifying and targeting the approach","volume":"17","author":"Fernandez","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0045","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/leu.2013.208","article-title":"The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo","volume":"27","author":"Todisco","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0046","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.2017.187450","article-title":"Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT","volume":"104","author":"Brissot","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0047","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/leu.2011.13","article-title":"Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia","volume":"25","author":"Craddock","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0048","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0049","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12032-013-0625-5","article-title":"Therapy-related acute promyelocytic leukemia: a systematic review","volume":"30","author":"Rashidi","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0050","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/cncr.30704","article-title":"Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach","volume":"123","author":"Boddu","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0051","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt Ostgard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0052","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0053","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ajh.25395","volume":"94","author":"Lee","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0054","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/bloodadvances.2018019976","article-title":"Conditioning intensity in secondary AML with prior myelodysplastic syndrome\/myeloproliferative disorders: an EBMT ALWP study","volume":"2","author":"Sengsayadeth","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2141.2006.06403.x","article-title":"Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial","volume":"136","author":"van der Holt","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0056","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2011.06.005","article-title":"Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission","volume":"17","author":"Farag","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0057","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbmt.2010.07.013","article-title":"Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission","volume":"17","author":"Kurosawa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0058","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood.2019003662","article-title":"Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?","volume":"135","author":"Ciurea","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0059","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0060","doi-asserted-by":"crossref","first-page":"e18501","DOI":"10.1200\/JCO.2016.34.15_suppl.e18501","volume":"34","author":"Niederwieser","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0061","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2019.05.037","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"Ringden","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0062","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(11)70326-6","article-title":"Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial","volume":"13","author":"Pfirrmann","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0063","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/leu.2014.332","article-title":"Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years","volume":"29","author":"Cornelissen","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0064","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1182\/blood-2011-07-370247","article-title":"Autologous peripheral blood stem cell transplantation for acute myeloid leukemia","volume":"118","author":"Vellenga","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0065","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(97)09214-3","article-title":"Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties","volume":"351","author":"Burnett","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0066","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0067","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-132405","article-title":"The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0068","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbmt.2008.05.017","article-title":"The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation","volume":"14","author":"Ballen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0069","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0070","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2015.98","article-title":"Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia","volume":"29","author":"Ruggeri","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0071","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.bbmt.2017.05.004","volume":"23","author":"Tong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0072","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/bmt.2016.182","article-title":"Clinical separation of cGvHD and GvL and better GvHD-free\/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML","volume":"52","author":"Zheng","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0073","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bbmt.2014.10.030","article-title":"Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type","volume":"21","author":"Warlick","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0074","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2011.10.016","article-title":"Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts","volume":"18","author":"Chen","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0075","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2009.05.014","article-title":"Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis","volume":"15","author":"Gutman","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0076","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2008-03-147041","article-title":"Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia","volume":"113","author":"Atsuta","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0077","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1470-2045(10)70127-3","article-title":"Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis","volume":"11","author":"Eapen","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0078","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3324\/haematol.2013.092254","article-title":"Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France","volume":"99","author":"Labopin","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0079","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1200\/JCO.18.00053","article-title":"Phase I\/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide","volume":"37","author":"Horwitz","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0080","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/bloodadvances.2019000200","article-title":"Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning","volume":"3","author":"van Besien","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0081","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/bmt.2016.20","article-title":"Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually","volume":"51","author":"Passweg","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0082","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0083","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0084","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbmt.2015.09.002","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0086","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.bbmt.2016.07.010","article-title":"Impact of donor type on outcome after allogeneic hematopoietic cell transplantation for acute leukemia","volume":"22","author":"Solomon","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0087","first-page":"105","article-title":"Safety and efficacy of haploidentical peripheral blood stem cell transplantation for myeloid malignancies using post-transplantation cyclophosphamide and anti-thymocyte globulin as graft-versus-host disease prophylaxis","volume":"1","author":"Salas","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0088","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","volume":"38","author":"Huang","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0089","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0090","article-title":"Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101)","author":"Fuchs","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0091","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/bloodadvances.2018021899","article-title":"Is a matched unrelated donor search needed for all allogeneic transplant candidates?","volume":"2","author":"Ciurea","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0092","first-page":"212","article-title":"T cell costimulation blockade with abatacept nearly eliminates early severe acute graft versus host disease after HLA-mismatched (7\/8 HLA matched) unrelated donor transplant, with a favorable impact on disease-free and overall survival","volume":"130","author":"Watkins","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0093","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.bbmt.2018.01.021","article-title":"Single antigen-mismatched unrelated hematopoietic stem cell transplantation using high-dose post-transplantation cyclophosphamide is a suitable alternative for patients lacking HLA-matched donors","volume":"24","author":"Jorge","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0094","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0095","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/bmt.2013.14","article-title":"Donor choice according to age for allo-SCT for AML in complete remission","volume":"48","author":"Ayuk","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0096","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/bmt.2015.180","article-title":"In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?","volume":"50","author":"Peffault de Latour","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0097","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/blood-2012-08-453860","article-title":"Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?","volume":"121","author":"Alousi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0098","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2018.02.006","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0099","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.leukres.2017.03.001","article-title":"Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: faster immune reconstitution using younger donors","volume":"57","author":"Gonzalez-Vicent","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0100","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","article-title":"Who is the best donor for a related HLA haplotype-mismatched transplant?","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0101","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","article-title":"Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ciurea","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0102","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/bloodadvances.2017014829","article-title":"Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide","volume":"2","author":"McCurdy","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0103","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ajh.24963","article-title":"Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation","volume":"93","author":"Canaani","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0104","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","article-title":"Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation","volume":"37","author":"Frick","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0106","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood.2019003079","article-title":"Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Boettcher","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0107","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials STEM CELL TRIALISTS","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0108","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0109","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jamaoncol.2016.2520","article-title":"Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial","volume":"2","author":"Lee","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3324\/haematol.2015.135699","article-title":"Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT","volume":"101","author":"Savani","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0111","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2014.57.2446","article-title":"Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation","volume":"33","author":"Eapen","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0112","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(09)70352-3","article-title":"Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial","volume":"11","author":"Friedrichs","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0113","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0114","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0115","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/cncr.31228","article-title":"Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide","volume":"124","author":"Ruggeri","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0116","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.critrevonc.2018.05.017","article-title":"Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide: a systematic review and meta-analysis","volume":"133","author":"Yu","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0117","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0118","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2011-05-352989","article-title":"Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study","volume":"119","author":"Lioure","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0119","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1089\/scd.2014.0123","article-title":"Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis","volume":"23","author":"Abdul Wahid","year":"2014","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0120","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial","volume":"13","author":"Bornhauser","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0121","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0122","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.bbmt.2019.12.075","volume":"26","author":"Scott","year":"2020","journal-title":"Bio Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0123","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2991\/chi.d.190218.002","article-title":"Current status and perspectives of irradiation-based conditioning regimens for patients with acute leukemia undergoing hematopoietic stem cell transplantation","volume":"1","author":"Potdar","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0125","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.2018874115","article-title":"Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation","volume":"133","author":"Baker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0126","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bmt.1701334","article-title":"Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan\/cyclophosphamide vs total body irradiation: a meta-analysis","volume":"22","author":"Hartman","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0127","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/ejh.12553","volume":"96","author":"Eder","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0128","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"Nagler","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0129","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","article-title":"Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation","volume":"122","author":"Bredeson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0130","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/ajh.25934","article-title":"Impact of total body irradiation- versus chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia","volume":"95","author":"Dholaria","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0131","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0132","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0133","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0134","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0135","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","article-title":"Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation","volume":"12","author":"Bacigalupo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0136","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","article-title":"Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial","volume":"4","author":"Finke","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0137","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0138","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0139","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40291-015-0147-2","article-title":"WT1 expression in circulating RNA as a minimal residual disease marker for AML patients after stem-cell transplantation","volume":"19","author":"Zhong","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0140","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2014-03-563403","article-title":"In adults with t(8;21)AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0141","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.leukres.2012.04.005","article-title":"Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia","volume":"36","author":"Miyazaki","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0142","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.25514","article-title":"Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse","volume":"94","author":"Press","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0143","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.leukres.2014.11.011","volume":"39","author":"Rossi","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0144","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0145","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/trf.12524","article-title":"Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Tan","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0146","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.bbmt.2014.05.025","article-title":"Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival","volume":"20","author":"Koreth","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0147","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","article-title":"Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Reshef","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0148","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbmt.2014.08.018","article-title":"Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults","volume":"21","author":"Peterlin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0149","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.23319","article-title":"Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation","volume":"87","author":"El-Cheikh","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0150","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.bbmt.2015.07.005","article-title":"Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0151","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/176526","article-title":"Very long term stability of mixed chimerism after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies","volume":"2015","author":"Levrat","year":"2015","journal-title":"Bone Marrow Res"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0152","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2991\/chi.d.190310.001","volume":"1","author":"Bazarbachi","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0153","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0154","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.bbmt.2018.12.077","article-title":"Radius: midostaurin (mido) plus standard of care (SOC) after allogeneic stem cell transplant (alloSCT) in patients (pts) with FLT3-internal tandem duplication (ITD)\u2013mutated acute myeloid leukemia (AML)","volume":"25","author":"Maziarz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0155","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0156","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0157","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0158","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1080\/10428194.2018.1443334","article-title":"Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies","volume":"59","author":"Maples","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0159","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0160","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0161","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.bbmt.2019.06.007","article-title":"A phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): results of CALGB 100801 (Alliance)","volume":"25","author":"Vij","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0162","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0163","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2018-99-111582","article-title":"Maintenance with 5-azacytidine for acute myeloid leukemia and myelodysplastic syndrome patients","volume":"132","author":"Oran","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0164","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15691","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia\u2014a matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"184","author":"Schmid","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0165","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/bmt.2014.2","volume":"49","author":"Solomon","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0166","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bbmt.2016.03.005","article-title":"Wilms tumor 1 expression and pre-emptive immunotherapy in patients with acute myeloid leukemia undergoing an allogeneic hemopoietic stem cell transplantation","volume":"22","author":"Di Grazia","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0167","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0168","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2012-11-466862","article-title":"Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia","volume":"121","author":"Yanada","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0169","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/bmt.2016.96","article-title":"Autologous transplant remains the preferred therapy for relapsed APL in CR2","volume":"51","author":"Ganzel","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0170","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2005.03.127","article-title":"Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group","volume":"23","author":"de Botton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0171","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2014.03.025","article-title":"Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission","volume":"20","author":"Holter Chakrabarty","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0172","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2991\/chi.d.190316.001","article-title":"Management of AML beyond \u201c3\u00a0+\u00a07\u201d in 2019","volume":"1","author":"Canaani","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0173","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0174","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.3324\/haematol.2017.186742","article-title":"NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed\/refractory acute myeloid leukemia patient","volume":"103","author":"Sallman","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0175","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41409-018-0383-2","article-title":"Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I\/II trial","volume":"54","author":"Kim","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0176","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0177","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0178","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3324\/haematol.2011.041004","article-title":"Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial","volume":"96","author":"Stelljes","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0179","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12185-009-0483-2","article-title":"Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study","volume":"91","author":"Sakamaki","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","article-title":"Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis","volume":"32","author":"Stelljes","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0181","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.2011.39.6499","article-title":"Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories","volume":"30","author":"Cornelissen","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0182","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0183","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0184","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0185","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.amjms.2016.02.034","article-title":"Prognosis of patients with de novo acute myeloid leukemia resistant to initial induction chemotherapy","volume":"351","author":"Wu","year":"2016","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0186","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2016.148825","article-title":"An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation","volume":"101","author":"Ferguson","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0187","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ajh.23655","article-title":"Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0188","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbmt.2014.10.025","article-title":"Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy","volume":"21","author":"Othus","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0189","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.bbmt.2018.04.008","article-title":"Transplant outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study","volume":"24","author":"Sengsayadeth","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0190","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3324\/haematol.2008.000927","article-title":"Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation","volume":"94","author":"Kr\u00f6ger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0191","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0192","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-016-0314-x","article-title":"Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT","volume":"9","author":"Saraceni","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0193","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/cncr.30400","volume":"123","author":"Gorin","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0194","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.25231","article-title":"Comparable outcomes of haploidentical, 10\/10 and 9\/10 unrelated donor transplantation in adverse karyotype AML in first complete remission","volume":"93","author":"Lorentino","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0195","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.3324\/haematol.2015.140509","volume":"101","author":"Sun","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0196","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0197","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bbmt.2017.01.068","article-title":"T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia","volume":"23","author":"How","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0198","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/s41409-019-0571-8","article-title":"Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission","volume":"54","author":"Yano","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0199","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.bbmt.2015.07.029","article-title":"High disease-free survival with enhanced protection against relapse after double-unit cord blood transplantation when compared with T cell-depleted unrelated donor transplantation in patients with acute leukemia and chronic myelogenous leukemia","volume":"21","author":"Ponce","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0200","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.bbmt.2014.02.020","article-title":"Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a Center for International Blood and Marrow Transplant Research-Eurocord analysis","volume":"20","author":"Weisdorf","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0201","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1158\/1078-0432.CCR-17-3622","article-title":"Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI-based regimen","volume":"24","author":"Baron","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0202","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-018-0598-0","article-title":"Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT","volume":"11","author":"Santoro","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0203","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/bloodadvances.2016002386","article-title":"Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1","volume":"1","author":"Versluis","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0204","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41409-019-0582-5","article-title":"Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT","volume":"54","author":"Ruggeri","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0205","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/bmt.2014.262","article-title":"High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT","volume":"50","author":"Hengeveld","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0206","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2015.02.014","article-title":"Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"21","author":"Malard","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0207","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.bbmt.2014.06.005","article-title":"Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy","volume":"20","author":"Nakaya","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0208","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajh.24677","article-title":"Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort","volume":"92","author":"Shouval","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0209","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/leu.2014.164","article-title":"Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission","volume":"29","author":"Versluis","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0210","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0211","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.bbmt.2016.08.030","article-title":"Myeloablative versus reduced-intensity conditioning in patients with myeloid malignancies: a propensity score-matched analysis","volume":"22","author":"Sibai","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0212","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringden","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0213","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/bloodadvances.2018021980","article-title":"Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity","volume":"2","author":"Eapen","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0214","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0215","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0216","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.2009.27.1460","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia","volume":"28","author":"Gyurkocza","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0217","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00277-018-3391-9","article-title":"Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies","volume":"97","author":"Khalil","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0218","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00432-017-2429-z","article-title":"Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis","volume":"143","author":"Zhang","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0219","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.2002.03973.x","article-title":"Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission","volume":"119","author":"Litzow","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0220","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/bloodadvances.2019000030","article-title":"Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI","volume":"3","author":"Nagler","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0221","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3324\/haematol.2019.227603","article-title":"Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin","volume":"105","author":"Baron","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0222","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-017-0043-y","volume":"53","author":"Devillier","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0223","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-0609.2008.01158.x","article-title":"Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia","volume":"82","author":"Candoni","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0224","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0225","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","article-title":"Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia","volume":"24","author":"Shah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0226","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.bbmt.2017.01.086","article-title":"Prognostic limitations of donor T cell chimerism after myeloablative allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"23","author":"Wong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0227","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0228","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ajh.24959","article-title":"Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant","volume":"93","author":"Sandmaier","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0229","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood.V128.22.1162.1162","article-title":"Prospective phase II study of prophylactic azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high risk acute myeloid leukemia and myelodysplastic syndrome","volume":"128","author":"Guillaume","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0230","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1399-0012.2012.01626.x","article-title":"Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study","volume":"26","author":"Wang","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0231","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbmt.2017.04.028","volume":"23","author":"Yan","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0232","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bbmt.2020.09.020_bib0233","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bbmt.2017.02.012","article-title":"Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan Marrow Donor Program","volume":"23","author":"Miyamoto","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387912030584X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387912030584X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:32:57Z","timestamp":1761089577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387912030584X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":233,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S108387912030584X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.020","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}